Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;33 Suppl 1(Suppl 1):S1-5.
doi: 10.1097/INF.0000000000000132.

Preparing for the scale-up of rotavirus vaccine introduction in Africa: establishing surveillance platforms to monitor disease burden and vaccine impact

Jason M Mwenda  1 , Jacqueline E Tate, A Duncan Steele, Umesh D Parashar
Affiliations

Preparing for the scale-up of rotavirus vaccine introduction in Africa: establishing surveillance platforms to monitor disease burden and vaccine impact

Jason M Mwenda et al. Pediatr Infect Dis J. 2014 Jan.

Abstract

Countries in Africa have begun introducing rotavirus vaccines in their national immunization programs, and wide-scale rollout across the continent is expected during the next few years. In preparation for vaccine introduction, many countries initiated surveillance for rotavirus and other studies to document disease burden, to describe the epidemiology and to monitor circulating rotavirus strains in Africa. In addition, 2 countries sought to systematically investigate cases of intussusception, a rare adverse event that has been associated with rotavirus vaccines in some settings. The ongoing surveillance provided data that will serve as a baseline against which the impact of rotavirus vaccines in Africa can be assessed.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Rotavirus vaccine introductions in Africa as of July 2013
Figure 2.
Figure 2.
Cumulative age distribution of rotavirus hospitalizations by 5 years of age for select countries.
See this image and copyright information in PMC

References

    1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. The Lancet infectious diseases. 2012;12(2):136–141. - PubMed
    1. Mwenda JM, Ntoto KM, Abebe A, Enweronu-Laryea C, Amina I, McHomvu J, et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. The Journal of infectious diseases. 2010;202 Suppl:S5–S11. - PubMed
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. The New England journal of medicine. 2006;354(1):23–33. - PubMed
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. The New England journal of medicine. 2006;354(1):11–22. - PubMed
    1. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–614. - PubMed

MeSH terms

Substances